Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection

Inclusion criteria

• Age 18 years or older, regardless of gender.
• Willing to undergo gastroscopy or able to provide postoperative esophageal biopsy pathological results.
• Newly diagnosed esophageal cancer patients (Stage I-IV) who have not undergone surgery, radiotherapy, chemotherapy, targeted therapy, or other tumor-related interventions prior to blood collection (for patients requiring neoadjuvant therapy, blood collection should be performed 1-2 days before neoadjuvant therapy; for patients not requiring neoadjuvant therapy, blood collection should be performed 1-2 days before surgery).

Exclusion criteria

• History of digestive system tumors, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, etc.
• History of other cancers that have not achieved clinical cure (clinical cure: no recurrence or metastasis within 5 years post-surgery).
• Systemic inflammatory response syndrome.
• Severe cardiovascular disease history (e.g., previous myocardial infarction, coronary artery bypass grafting, or coronary stent implantation; history of congestive heart failure; myocardial infarction within the past 6 months; uncontrolled severe hypertension, etc.) and deemed unsuitable for inclusion by the investigator.
• Patients who have undergone blood transfusion or major surgical procedures such as transplantation within the past 3 months.
• Participation in other interventional clinical studies within the past 3 months, or individuals who are pregnant, breastfeeding, or have autoimmune diseases, genetic disorders, mental illnesses, etc.
• Participation in "interventional" clinical trials and use of investigational drugs within the past 30 days.
• Other diseases deemed unsuitable for inclusion by the investigator.
• Failure to adhere to the study plan for timely blood collection.
• Blood samples that do not meet the requirements (unqualified samples include: ① clotted samples; ② hemolyzed samples; ③ insufficient sample volume; ④ samples delivered for testing more than 72 hours after collection; ⑤ incorrect sample information; ⑥ severe lipemia, with blood appearing milky; ⑦ damaged collection tubes or contaminated samples, etc.).